AltPep, a Seattle-based biotech startup tackling amyloid protein disorders, has raised $23.1 million in a Series A funding round. The venture spun out the University of Washington in March 2019. Its founder and CEO is Valerie Daggett, a longtime professor in the Department of Bioengineering in the College of Engineering. AltPep is developing tools and treatments for diseases caused by amyloid proteins that are incorrectly folded and create harmful deposits. These deposits can lead to numerous amyloid diseases including Alzheimer’s, Parkinson’s, type-2 diabetes, some kinds of drug-resistant bacterial infections, and dozens more.